在印度北部转移性前列腺癌男性队列中检测到前列腺相关种系变异频率。

IF 5.6 2区 医学 Q1 ONCOLOGY
JCO precision oncology Pub Date : 2025-07-01 Epub Date: 2025-07-10 DOI:10.1200/PO-25-00130
Atul Batra, Jessica G Cockburn, Abhenil Mittal, Rui M Bernardino, Tiiu Sildva, Marian Severin Wettstein, Amlesh Seth, Brusabhanu Nayak, Sameer Bakhshi, Ranjit K Sahoo, Akash Kumar, Rishabh Jain, Seema Kaushal, Mayank Singh, Sneha Gund, Sunakshi Chowdhary, Karina Lakhani, Krishna Patel, Raymond H Kim, Mohammad R Akbari, Neil Eric Fleshner
{"title":"在印度北部转移性前列腺癌男性队列中检测到前列腺相关种系变异频率。","authors":"Atul Batra, Jessica G Cockburn, Abhenil Mittal, Rui M Bernardino, Tiiu Sildva, Marian Severin Wettstein, Amlesh Seth, Brusabhanu Nayak, Sameer Bakhshi, Ranjit K Sahoo, Akash Kumar, Rishabh Jain, Seema Kaushal, Mayank Singh, Sneha Gund, Sunakshi Chowdhary, Karina Lakhani, Krishna Patel, Raymond H Kim, Mohammad R Akbari, Neil Eric Fleshner","doi":"10.1200/PO-25-00130","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Although prostate cancer is generally associated with favorable outcomes, metastatic disease remains incurable. Additionally, a subset of individuals with high-risk or metastatic disease are likely to harbor at least one germline variant in known prostate cancer association genes. Because of differences in cohort selection and sequencing strategies, the prevalence of germline variants in global populations is unclear.</p><p><strong>Methods: </strong>A whole-exome sequencing (WES) approach was used to explore germline variants in a cohort of patients with metastatic prostate cancer from India. In total, 276 individuals treated at the All India Institute of Medical Sciences in New Delhi, India, were prospectively and consecutively recruited. Blood specimens underwent standard WES and bioinformatic analysis to determine the prevalence of pathogenic and likely pathogenic (PV/LPV) prostate cancer variants, which were then assessed for associations with clinical features.</p><p><strong>Results: </strong>In total, PV/LPVs were detected in 11% of individuals across eight genes linked to prostate cancer, most frequently in BRCA2 (3.98%). The distribution reflects previously published findings from other global cohorts, although frequencies in the prevalence of specific variants differ slightly. No relationship between variant status and clinical features were detected, although analysis of a larger cohort may show otherwise.</p><p><strong>Conclusion: </strong>These results indicate that germline screening for prostate cancer following existing guidelines yield similar variant detection frequencies when focusing on individuals with metastatic disease in the Indian context. In summary, some men are more likely to develop an advanced form of metastatic prostate cancer than others because of differences in their genes, known as variants. This study looked at the how many of these variants are in a group of patients from India. We found that the number of variants in this group was similar to those from other parts of the world, including more found in a gene called <i>BRCA2</i>.</p>","PeriodicalId":14797,"journal":{"name":"JCO precision oncology","volume":"9 ","pages":"e2500130"},"PeriodicalIF":5.6000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262130/pdf/","citationCount":"0","resultStr":"{\"title\":\"Prostate-Related Germline Variant Frequencies Detected in a Cohort of Men With Metastatic Prostate Cancer in Northern India.\",\"authors\":\"Atul Batra, Jessica G Cockburn, Abhenil Mittal, Rui M Bernardino, Tiiu Sildva, Marian Severin Wettstein, Amlesh Seth, Brusabhanu Nayak, Sameer Bakhshi, Ranjit K Sahoo, Akash Kumar, Rishabh Jain, Seema Kaushal, Mayank Singh, Sneha Gund, Sunakshi Chowdhary, Karina Lakhani, Krishna Patel, Raymond H Kim, Mohammad R Akbari, Neil Eric Fleshner\",\"doi\":\"10.1200/PO-25-00130\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Purpose: </strong>Although prostate cancer is generally associated with favorable outcomes, metastatic disease remains incurable. Additionally, a subset of individuals with high-risk or metastatic disease are likely to harbor at least one germline variant in known prostate cancer association genes. Because of differences in cohort selection and sequencing strategies, the prevalence of germline variants in global populations is unclear.</p><p><strong>Methods: </strong>A whole-exome sequencing (WES) approach was used to explore germline variants in a cohort of patients with metastatic prostate cancer from India. In total, 276 individuals treated at the All India Institute of Medical Sciences in New Delhi, India, were prospectively and consecutively recruited. Blood specimens underwent standard WES and bioinformatic analysis to determine the prevalence of pathogenic and likely pathogenic (PV/LPV) prostate cancer variants, which were then assessed for associations with clinical features.</p><p><strong>Results: </strong>In total, PV/LPVs were detected in 11% of individuals across eight genes linked to prostate cancer, most frequently in BRCA2 (3.98%). The distribution reflects previously published findings from other global cohorts, although frequencies in the prevalence of specific variants differ slightly. No relationship between variant status and clinical features were detected, although analysis of a larger cohort may show otherwise.</p><p><strong>Conclusion: </strong>These results indicate that germline screening for prostate cancer following existing guidelines yield similar variant detection frequencies when focusing on individuals with metastatic disease in the Indian context. In summary, some men are more likely to develop an advanced form of metastatic prostate cancer than others because of differences in their genes, known as variants. This study looked at the how many of these variants are in a group of patients from India. We found that the number of variants in this group was similar to those from other parts of the world, including more found in a gene called <i>BRCA2</i>.</p>\",\"PeriodicalId\":14797,\"journal\":{\"name\":\"JCO precision oncology\",\"volume\":\"9 \",\"pages\":\"e2500130\"},\"PeriodicalIF\":5.6000,\"publicationDate\":\"2025-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12262130/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"JCO precision oncology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1200/PO-25-00130\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/7/10 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"JCO precision oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1200/PO-25-00130","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/7/10 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:虽然前列腺癌通常与良好的预后相关,但转移性疾病仍然无法治愈。此外,一小部分高风险或转移性疾病患者可能在已知的前列腺癌相关基因中携带至少一种种系变异。由于队列选择和测序策略的差异,种系变异在全球人群中的流行程度尚不清楚。方法:采用全外显子组测序(WES)方法研究印度转移性前列腺癌患者的种系变异。在印度新德里全印度医学科学研究所接受治疗的276人被前瞻性和连续招募。血液标本进行标准WES和生物信息学分析,以确定致病性和可能致病性(PV/LPV)前列腺癌变异的患病率,然后评估其与临床特征的相关性。结果:总的来说,PV/LPVs在与前列腺癌相关的8个基因中的11%的个体中检测到,最常见的是BRCA2(3.98%)。该分布反映了先前发表的其他全球队列的研究结果,尽管特定变体的流行频率略有不同。没有发现变异状态和临床特征之间的关系,尽管对更大队列的分析可能会显示出相反的结果。结论:这些结果表明,在印度背景下,当关注转移性疾病个体时,遵循现有指南的前列腺癌生殖系筛查产生相似的变异检测频率。总而言之,一些男性比其他人更容易患上晚期转移性前列腺癌,因为他们的基因存在差异,也就是变异。这项研究观察了一组来自印度的患者中有多少这些变异。我们发现,这一群体的变异数量与世界上其他地区的人相似,其中在一种名为BRCA2的基因中发现了更多的变异。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Prostate-Related Germline Variant Frequencies Detected in a Cohort of Men With Metastatic Prostate Cancer in Northern India.

Purpose: Although prostate cancer is generally associated with favorable outcomes, metastatic disease remains incurable. Additionally, a subset of individuals with high-risk or metastatic disease are likely to harbor at least one germline variant in known prostate cancer association genes. Because of differences in cohort selection and sequencing strategies, the prevalence of germline variants in global populations is unclear.

Methods: A whole-exome sequencing (WES) approach was used to explore germline variants in a cohort of patients with metastatic prostate cancer from India. In total, 276 individuals treated at the All India Institute of Medical Sciences in New Delhi, India, were prospectively and consecutively recruited. Blood specimens underwent standard WES and bioinformatic analysis to determine the prevalence of pathogenic and likely pathogenic (PV/LPV) prostate cancer variants, which were then assessed for associations with clinical features.

Results: In total, PV/LPVs were detected in 11% of individuals across eight genes linked to prostate cancer, most frequently in BRCA2 (3.98%). The distribution reflects previously published findings from other global cohorts, although frequencies in the prevalence of specific variants differ slightly. No relationship between variant status and clinical features were detected, although analysis of a larger cohort may show otherwise.

Conclusion: These results indicate that germline screening for prostate cancer following existing guidelines yield similar variant detection frequencies when focusing on individuals with metastatic disease in the Indian context. In summary, some men are more likely to develop an advanced form of metastatic prostate cancer than others because of differences in their genes, known as variants. This study looked at the how many of these variants are in a group of patients from India. We found that the number of variants in this group was similar to those from other parts of the world, including more found in a gene called BRCA2.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
9.10
自引率
4.30%
发文量
363
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信